Routine betamethasone therapy of non-hydropic fetuses with CPAM – the way to improve perinatal outcome?

Authors discuss novel approach to the management of fetal congenital pulmonary cystic malformation (CPAM) and possible benefit routine administration betamethasone, which is currently recommended only for severe cases. The article presents authors' own experience with antenatally diagnosed CPAM describes 4 cases prenatally without hydrops treated by two doses betamethasone at 21-31 weeks gestation aim improving perinatal prognosis effect on not mortality but also postnatal morbidity. Article summarizes current knowledge all aspects prenatal focusing its treatment options. Data were obtained from literature search based PubMed Scopus database additional particular articles reference list selected publications.All patients case reports showed regression mass after maternal 100 % survival rate. Even though it say if was due treatment, we did observe any complication in relation survived until discharge. During search, find data non-hydropic fetuses overall morbidity, neither comparing outcome between versus observed fetuses.Routine should be discussed order reduce morbidity associated (Tab. 1, Ref. 47). Keywords: (congenital adenomatoid malformation), therapy.